|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7800 HKD | +5.41% |
|
+9.86% | +39.29% |
Company Valuation: Zhongzhi Pharmaceutical Holdings Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 968.7 | 1,181 | 696.5 | 832.7 | 1,113 | 803.4 |
| Change | - | 21.94% | -41.03% | 19.55% | 33.68% | -27.82% |
| Enterprise Value (EV) 1 | 708 | 1,058 | 614.4 | 607.8 | 1,096 | 792.3 |
| Change | - | 49.45% | -41.93% | -1.07% | 80.26% | -27.69% |
| P/E ratio | 8.38x | 8.41x | 13.4x | 7.68x | 6.78x | 8.46x |
| PBR | 1.27x | 1.44x | 0.77x | 0.83x | 1.06x | 0.72x |
| PEG | - | 0.4x | -0.2x | 0x | 0.1x | -0.2x |
| Capitalization / Revenue | 0.72x | 0.74x | 0.4x | 0.46x | 0.54x | 0.36x |
| EV / Revenue | 0.53x | 0.66x | 0.35x | 0.33x | 0.53x | 0.36x |
| EV / EBITDA | 4.25x | 5.07x | 5.02x | 3.95x | 5.1x | 4.6x |
| EV / EBIT | 5.18x | 7.14x | 7.72x | 5.87x | 6.68x | 6.33x |
| EV / FCF | 11.2x | -27.9x | -12.5x | 2.74x | -10.5x | 28.7x |
| FCF Yield | 8.92% | -3.58% | -8.03% | 36.4% | -9.5% | 3.48% |
| Dividend per Share 2 | 0.0541 | 0.0312 | - | 0.0531 | 0.0817 | 0.047 |
| Rate of return | 4.69% | 2.22% | - | 5.5% | 6.34% | 5.05% |
| EPS 2 | 0.1376 | 0.1671 | 0.06 | 0.1256 | 0.19 | 0.11 |
| Distribution rate | 39.3% | 18.6% | - | 42.3% | 43% | 42.7% |
| Net sales 1 | 1,342 | 1,604 | 1,746 | 1,826 | 2,050 | 2,215 |
| EBITDA 1 | 166.5 | 208.6 | 122.3 | 153.9 | 214.8 | 172.3 |
| EBIT 1 | 136.8 | 148.2 | 79.58 | 103.5 | 163.9 | 125.1 |
| Net income 1 | 114.7 | 138.5 | 52.13 | 106.4 | 162.8 | 95.21 |
| Net Debt 1 | -260.7 | -123.1 | -82.1 | -224.8 | -17.45 | -11.09 |
| Reference price 2 | 1.1532 | 1.4062 | 0.8065 | 0.9642 | 1.2889 | 0.9303 |
| Nbr of stocks (in thousands) | 8,40,000 | 8,40,000 | 8,63,600 | 8,63,600 | 8,63,600 | 8,63,600 |
| Announcement Date | 14/04/20 | 14/04/21 | 19/04/22 | 20/04/23 | 19/04/24 | 16/04/25 |
1CNY in Million2CNY
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 8.64Cr | ||
| 34.9x | 6.42x | 22.52x | 0.89% | 4.26TCr | ||
| 14.79x | 1.88x | 7.79x | 1.53% | 3.13TCr | ||
| 25.45x | 3.57x | 16.94x | 1.09% | 1.16TCr | ||
| 19.32x | 3.34x | 12.38x | 0.79% | 965.98Cr | ||
| 17.53x | 3.11x | 11.43x | 3.67% | 798.77Cr | ||
| 81.64x | - | - | 1.1% | 786.91Cr | ||
| 16.03x | 2.02x | 8x | 3.41% | 681.2Cr | ||
| 24.43x | 3.29x | 15.36x | 0.14% | 604.39Cr | ||
| Average | 29.26x | 3.37x | 13.49x | 1.58% | 1.38TCr | |
| Weighted average by Cap. | 28.02x | 4.01x | 15.16x | 1.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- 3737 Stock
- Valuation Zhongzhi Pharmaceutical Holdings Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















